Highlights

  • Neuren shares declined 7.84% to AUD 12.69 on 3 March 2026.
  • Six-month performance shows a 33.21% decline amid regulatory uncertainty.
  • Broker consensus target of AUD 23.83 implies 87.79% upside.

Neuren Pharmaceuticals Limited (ASX:NEU) closed at AUD 12.69 on 3 March 2026, down AUD 1.08 or 7.84% for the session. The decline followed confirmation that partner Acadia Pharmaceuticals plans to request a re-examination of the CHMP opinion regarding trofinetide’s European marketing application.

The stock traded within a tight bid-offer range of AUD 12.680 to AUD 12.690, with volume reaching 418,332 shares. Neuren’s market capitalisation currently stands at AUD 1.74 billion.

Short-Term Movement Reflects Regulatory Impact

The immediate weakness reflects developments related to trofinetide’s Marketing Authorization Application in Europe. The Committee for Medicinal Products for Human Use (CHMP) formally confirmed its earlier trend vote recommending refusal of approval.

Trofinetide is already approved in the United States, Canada and Israel for Rett syndrome. However, the European process has introduced uncertainty into the near-term outlook, influencing recent trading activity.

Despite the daily decline, the stock has gained 3.17% over the past five trading days, suggesting volatility around regulatory headlines rather than a sustained directional move in the very short term.

Medium-Term Trend Shows Extended Pullback

Over the past month, Neuren shares have declined 13.26%. The six-month performance shows a 33.21% drop, while year-to-date losses stand at 32.89%. On a 12-month basis, the stock is down 3.94%.

These figures indicate that recent weakness forms part of a broader consolidation phase following earlier gains. Over a five-year horizon, the stock remains up 915.20%, reflecting substantial long-term appreciation despite current volatility.

Regulatory Re-Examination in Focus

Acadia confirmed plans to seek re-examination of the CHMP opinion. The agency cited perceived deficits including the magnitude of treatment effect after 12 weeks, limited capture of core Rett syndrome symptoms, and longer-term assessment complexities influenced by patient discontinuations.

Neuren CEO Jon Pilcher commented:
“Neuren fully supports a re-examination of the CHMP opinion. Trofinetide has been making a difference for patients for nearly three years in approved markets and the unmet medical need in Europe remains substantial and urgent.”

The outcome of the re-examination process may influence sentiment in the months ahead.

Broker Consensus Indicates Valuation Gap

According to EODHD/Others data as of 03 March 2026, the current consensus recommendation sits at 1.83, classified as BUY. The average price target is AUD 23.83, representing an implied upside of 87.79% from the latest closing price.

While the share price has retreated in recent months, analyst targets suggest expectations of recovery relative to present levels. Market participants will likely monitor regulatory developments and commercial progress in approved regions.

Neuren Pharmaceuticals fell 7.84% to AUD 12.69 following confirmation of a CHMP refusal opinion for trofinetide in Europe. The stock has declined more than 33% over six months amid regulatory uncertainty. Despite the pullback, broker consensus remains at BUY with an average target of AUD 23.83, implying notable valuation upside from current levels.

FAQs

  1. Why did Neuren shares fall on 3 March 2026?
    Neuren declined after confirmation of the CHMP’s refusal opinion on trofinetide’s European marketing application.
  2. How has NEU performed over the past six months?
    The stock has fallen 33.21% over six months amid regulatory developments and sentiment shifts.
  3. What is the current broker target price for NEU?
    The consensus average target price is AUD 23.83, implying 87.79% upside from AUD 12.69.